Premium
Nongastric marginal zone B‐cell lymphoma: Analysis of 247 cases
Author(s) -
Oh Sung Yong,
Ryoo BaekYeol,
Kim Won Seog,
Park Yeon Hee,
Kim Kihyun,
Kim Hyun Jung,
Kwon Jung Mi,
Lee Jeeyun,
Ko Young Hye,
Ahn Yong Chan,
Oh Suk Joong,
Lee Soon Il,
Kim HyoJin,
Kwon HyukChan,
Bang Soo Mee,
Kim Jung Han,
Park Jinny,
Lee SeungSook,
Kim Ho Young,
Park Keunchil
Publication year - 2007
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.20874
Subject(s) - international prognostic index , medicine , b symptoms , follicular lymphoma , stage (stratigraphy) , gastroenterology , lymphoma , progression free survival , marginal zone b cell lymphoma , marginal zone , surgery , rituximab , chemotherapy , b cell , immunology , paleontology , antibody , biology
Nongastric marginal zone B‐cell lymphoma (NG‐MZL) is a relatively uncommon indolent lymphoma. From 1990 to 2005, a total of 247 patients with histologically confirmed NG‐MZL were analyzed. Ann Arbor stage I/II disease was present in 78% (167 out of 215). One hundred eighty‐six patients out of two hundred eight were categorized into the low/low‐intermediate risk group (89%) according to International Prognostic Index (IPI). Eighty percent (172/215) were in low risk group according to Follicular Lymphoma International Prognostic Index (FLIPI). Complete and partial remissions (CR and PR) were achieved in 140 (92.7%) and 8 (5.3%) of the 151 stage I/II patients. Especially, radiation containing treatment achieved 96% CR rate (108 out of 113). In 38 patients with stage III/IV, CR and PR were achieved in 17 (44.7%) and 11 (26.3%), respectively. The estimated five‐year overall survival (OS) and progression‐free survival (PFS) were 93.8% and 70.1%, respectively. Although anthracycline‐containing regimen could achieve higher CR rate, it did not improve PFS. Stage III/IV, low hemoglobin, poor performance status, high/high‐intermediate IPI, poor risk FLIPI, and nodal MZL were poor prognostic factors for PFS. NG‐MZL is an indolent disease. FLIPI has strong power to predict the prognosis of NG‐MZL. Am. J. Hematol., 2007. © 2007 Wiley‐Liss, Inc.